Novartis cuts jobs to counter losses

Share this article:

Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and the impact of ugly study results on Tekturna sales.

The cuts will take effect in the second quarter, with the affected reps and managers to be notified in early April, the company said.

“We recognize that the next two years will be challenging in the Pharmaceuticals Division and we are proactively making these changes to further focus our pipeline on the best opportunities and align our market position on our growth brands,” said David Epstein, division head at Novartis Pharmaceuticals. “These are difficult but necessary decisions that will free up resources to invest in the future of our business, which we view as well suited to bring new valuable therapies to patients and payors.”

Renin inhibitor Diovan loses exclusivity in September, and a planned round of cuts was accelerated following the early shutdown of the firm's ALTITUDE trial of aliskiren (marketed as Tekturna in the US) due to a finding of increased risk of serious side effects including non-fatal stroke, renal complications, hyperkalemia and hypotension. Novartis pulled all promotion of the hypertension drug, once expected to be a blockbuster.

Novartis forecast an exceptional charge of $160 million to be taken in first quarter results, and said the cuts would produce full-year savings of around $450 million in 2013, with around half of that to be realized in 2012. The company will take a charge of around $900 million to fourth quarter results in recognition of the ALTITUDE study's impact on Tekturna sales.

The company is also taking a $160 million exceptional charge in the fourth quarter to account for termination of two experimental drug programs—for PRT128 (elinogrel) and SMC021 (oral calcitonin).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...